//
// file taut_enum_protonate_a.smk
// David Cosgrove
// AstraZeneca
// 24th December 2013
//

#ifndef TAUT_ENUM_PROTONATE_A_SMK
#define TAUT_ENUM_PROTONATE_A_SMK

#include <string>

namespace DACLIB {

static const std::string PROTONATE_A = "\n\
########################################################################\n\
# made into SMIRKS by Dave Cosgrove December 2013\n\
########################################################################\n\
#\n\
#  set_prot_a.smt_v1.2                              PW Kenny 15-Aug-2005\n\
#\n\
#  SBDE First step ionisation SMARTS  Version 1.2      \n\
#\n\
#  These SMARTS were generated by making sbde_standardise.smt_v1.1\n\
#  SMARTS compatible with both Daylight and OEChem which differ in \n\
#  their use of the R and r descriptors.  \n\
#\n\
#  The SMARTS definitions in this file are the property of \n\
#  AstraZeneca and must not be distributed or otherwise made \n\
#  available outside the Company\n\
#\n\
########################################################################\n\
#\n\
#  Protonation states are set in two steps.  These\n\
#  molecular edit directives control the first of these\n\
#  steps which ionises functional groups for which the\n\
#  ionised form predominates to the extent that the\n\
#\n\
#------------------------------------------------------------\n\
#\n\
#  Aliphatic amines\n\
#\n\
#  Bis-ethylene diamine needs to be attended to first because\n\
#  the nitrogens of its neutral form will individually match\n\
#  aliphatic amine SMARTS \n\
#\n\
#[$AlipAmin;!$NTriAm]CC[$NTriAm]CC[$AlipAmin;!$NTriAm]\n\
#Prt 1  1\n\
#Prt 7  1\n\
[$AlipAmin;!$NTriAm:1][C:2][C:3][$NTriAm:4][C:5][C:6][$AlipAmin;!$NTriAm:7]>>[*+:1]([H])[*:2][*:3][*:4][*:5][*:6][*+1:7][H] PROT_A_1\n\
#\n\
#   Protonation of N-benzylpiperazine nitrogen is enumerated\n\
#   so allow other nitrogen in piperazine to protonate first\n\
#   to avoid the M371583 problem. \n\
# \n\
#[$AlipAmin;!$N2Cat;!$N1Cat;!$(N(CN)CN);!$(N(CN)CCN);!$(NCa)]\n\
#Prt 1  1\n\
[$AlipAmin;!$N2Cat;!$N1Cat;!$(N(CN)CN);!$(N(CN)CCN);!$(NCa):1]>>[*+:1][H] PROT_A_2\n\
#\n\
#[$AlipAmin;!$N2Cat;!$N1Cat;!$(N(CN)CN);!$(N(CN)CCN)]\n\
#Prt 1  1\n\
[$AlipAmin;!$N2Cat;!$N1Cat;!$(N(CN)CN);!$(N(CN)CCN):1]>>[*+:1][H] PROT_A_3\n\
#\n\
#  Alkyl hydrazines will be properly enumerated later\n\
#[$am]-[$am]\n\
#Prt 1  1\n\
[$am:1]-[$am:2]>>[*+:1]([H])-[*:2] PROT_A_4\n\
#      \n\
#------------------------------------------------------------\n\
#\n\
#  Basic sp2 nitrogen [e.g. guanidines, amidines & \n\
#                      heteroaromatic nitrogen]\n\
#\n\
#[$GuanPrt0,$GuanPrt1,$GuanPrt2,$FamdPrt0,$FamdPrt1,$FamdPrt2]\n\
#Prt  1  1\n\
[$GuanPrt0,$GuanPrt1,$GuanPrt2,$FamdPrt0,$FamdPrt1,$FamdPrt2:1]>>[*+:1][H] PROT_A_5\n\
#\n\
#  4-Aminopyridines and imine analogues\n\
#\n\
#[$AmPyrid4a]\n\
#Prt 1  1\n\
[$AmPyrid4a:1]>>[*+:1][H] PROT_A_6\n\
#[$im,$nph]=c1[$c13][$c13][nX3]([C&X4,$c12])[$c13][$c13]1\n\
#Prt 1  1\n\
[$([$im,$nph]=c1[$c13][$c13][nX3]([C&X4,$c12])[$c13][$c13]1):1]>>[*+:1][H] PROT_A_7\n\
#\n\
#------------------------------------------------------------\n\
#\n\
#  Oxygen acids [sufficiently acidic non aromatic enols \n\
#  will be deprotonated from their keto forms as carbon\n\
#  acids]  \n\
#    \n\
#  Carboxylate, sulfonate & difluorophosphonate\n\
#[OH][$(C),$(S),$(PC(F)F)]=O\n\
#Prt  1  -1\n\
[H][$([OH][$(C),$(S),$(PC(F)F)]=O):1]>>[*-:1] PROT_A_8\n\
#\n\
#  Remove only one proton from phosph(on)ates; the other\n\
#  will be handled in subsequent enumeration step\n\
#\n\
#[OH]P(=O)([O;!-])[A,a;!-]\n\
#Prt  1  -1\n\
[H][$([OH]P(=O)([O;!-])[A,a;!-]):1]>>[*-:1] PROT_A_9\n\
#\n\
#  4-Hydroxypyrones, pyridones & ring-fused analogues [pKa: 4-5]\n\
#\n\
#[o,n&X3]1c([OH])[$c3]c(=O)[$c3][$c3]1\n\
#Prt  3  -1\n\
#[o,n&X3:1]1[c:2]([OH:3][H])[$c3:4][c:5](=[O:6])[$c3:7][$c3:8]1>>[*:1]1[*:2]([*-:3])[*:4][*:5](=[*:6])[*:7][*:8]1 PROT_A_10\n\
[H][$([OH]c([o,n&X3]1)[$c3]c(=O)[$c3][$c3]1):1]>>[*-:1] PROT_A_10\n\
#O=c1[$c3]c([OH])[$c3][$c3][o,n&X3]1\n\
#Prt  5  -1\n\
[H][$([OH]c([$c3]c1=O)[$c3][$c3][o,n&X3]1):1]>>[*-:1] PROT_A_11\n\
#\n\
#  Variations on hydroxypyrones [eg M387090]\n\
#\n\
#[OH]c1[$c3]c(=O)[$XOHNeu][$XOHNeu][$XOHNeu]1\n\
#Prt  1  -1\n\
[H][$([OH]c1[$c3]c(=O)[$XOHNeu][$XOHNeu][$XOHNeu]1):1]>>[*-:1] PROT_A_12\n\
#\n\
#  6-Hydroxypyrones, pyridones & ring-fused analogues [pKa-DB\n\
#  lists value of 3.75 for bland pyridone M090753] \n\
#\n\
#[OH]c1[o,n&X3]c(=O)[$c3][$c3][$c3]1\n\
#Prt  1  -1\n\
[H][$([OH]c1[o,n&X3]c(=O)[$c3][$c3][$c3]1):1]>>[*-:1] PROT_A_13\n\
#\n\
#   Maleic hydrazide & analogues\n\
#\n\
#[OH]c1[nX2][nX3]c(=O)cc1\n\
#Prt  1  -1\n\
[H][$([OH]c1[nX2][nX3]c(=O)cc1):1]>>[*-:1] PROT_A_14\n\
#\n\
#   N-Hydroxypyridones\n\
#\n\
#[OH]n1c(=O)aaaa1\n\
#Prt  1  -1\n\
[H][$([OH]n1c(=O)aaaa1):1]>>[*-:1] PROT_A_15\n\
#[OH]n1aac(=O)aa1\n\
#Prt  1  -1\n\
[H][$([OH]n1aac(=O)aa1):1]>>[*-:1] PROT_A_16\n\
#\n\
#   Other N-hydroxy heterocyles [see JMC 2002, v45, p19]\n\
#\n\
#[OH]n1[nX2][c,n&X2][c,n&X2][c,n&X2]1\n\
#Prt  1  -1\n\
[H][$([OH]n1[nX2][c,n&X2][c,n&X2][c,n&X2]1):1]>>[*-:1] PROT_A_17\n\
#\n\
#-------------------------------------------------------------------\n\
#\n\
#  Tetrazoles [both tautomers]\n\
#\n\
#[nH]1[nX2][nX2][nX2]c1\n\
#Prt  1  -1\n\
[H][$([nH]1[nX2][nX2][nX2]c1):1]>>[*-:1] PROT_A_18\n\
#[nH]1[nX2][nX2]c[nX2]1\n\
#Prt  1  -1\n\
[H][$([nH]1[nX2][nX2]c[nX2]1):1]>>[*-:1] PROT_A_19\n\
#\n\
#   Acidic sulfonamides [defined in vector binding file...there\n\
#   is also a set of these targeted for enumeration]\n\
#\n\
#[$Sulfam1]\n\
#Prt  1  -1 \n\
[H][$Sulfam1:1]>>[*-:1] PROT_A_20\n\
#\n\
#  Cyclic imides from QSAR 1991, v10, p109; some related\n\
#  types such as TZDs will be enumerated in a subsequent step\n\
#\n\
#O=C1[NH]C(=O)[O,$(C=O)][N,C]1\n\
#Prt  3  -1\n\
[H][$([NH](C1=O)C(=O)[O,$(C=O)][N,C]1):1]>>[*-:1] PROT_A_21\n\
#\n\
#  Isoxazolones and related structures [see JMC 1997, v40\n\
#  p520 & 1196, v39, p5228] a number of less acidic related \n\
#  types such as pyrazolones will be enumerated in a \n\
#  subsequent step\n\
#\n\
#O=c1[nH]o[n&X2,$c3][$c3]1\n\
#Prt  3  -1\n\
[H][$([nH](c1=O)o[n&X2,$c3][$c3]1):1]>>[*-:1] PROT_A_22\n\
#O=c1o[nH][n&X2,$c3][$c3]1\n\
#Prt  4  -1\n\
[H][$([nH](oc1=O)[n&X2,$c3][$c3]1):1]>>[*-:1] PROT_A_23\n\
#\n\
#[nH]1[nX2][$c3][o,s]c1=[S;X1]\n\
#Prt  1  -1\n\
[H][$([nH]1[nX2][$c3][o,s]c1=[S;X1]):1]>>[*-:1] PROT_A_24\n\
#\n\
#  Analogs of M263635 [pKa-DB lists value of 5.11]  \n\
#\n\
#[NH]1S(=O)ON=C1\n\
#Prt  1  -1\n\
[H][$([NH]1S(=O)ON=C1):1]>>[*-:1] PROT_A_25\n\
#[NH]1OS(=O)N=C1\n\
#Prt  1  -1\n\
# nothing like 26 in ISAC at the moment, I don't think. (DAC, 15/8/2013)\n\
[H][$([NH]1OS(=O)N=C1):1]>>[*-:1] PROT_A_26\n\
#\n\
#  Sulfonyl analogues of pyrimidine-diones [see Tet 1999,\n\
#  v55, p12405]\n\
#\n\
#[NH]1C(=O)[N;X3;!H]S(=O)(=O)[C&X3,a]~[C&X3,a]1\n\
#Prt  1  -1\n\
[H][$([NH]1C(=O)[N;X3;!H]S(=O)(=O)[C&X3,a]~[C&X3,a]1):1]>>[*-:1] PROT_A_27\n\
#[NH]1S(=O)(=O)[N;X3;!H]C(=O)[C&X3,a]~[C&X3,a]1\n\
#Prt  1  -1\n\
[H][$([NH]1S(=O)(=O)[N;X3;!H]C(=O)[C&X3,a]~[C&X3,a]1):1]>>[*-:1] PROT_A_28\n\
#\n\
#  Sulfonyl triazoles [see Pestic Sci 1990, v29, p227]\n\
#\n\
#[$SO2trz]\n\
#Prt  1  -1\n\
[H][$([$SO2trz]):1]>>[*-:1] PROT_A_29\n\
#\n\
#  Another obscure potential phosphate mimic [pKa: 4.5-5.5]\n\
#\n\
#[NH]1cc[O,N&X3&!-]S1(=O)=O\n\
#Prt  1  -1\n\
[H][$([NH]1cc[O,N&X3&!-]S1(=O)=O):1]>>[*-:1] PROT_A_30\n\
#\n\
#--------------------------------------------------------------\n\
#\n\
#  Carbon acids...these definitions will nail a dazzling\n\
#  array of targets...but will the scorers notice\n\
#\n\
#  Cyclic 1,3-diketones and sulfoxide analogues [includes \n\
#  species in QSAR 1991, v10, p109]\n\
#\n\
#O=[C,S;$R]-;@[C;H,H2;!-]-;@[C,S;$R](=O)\n\
#Prt 3  -1\n\
[H][$([C;H,H2;!-](-;@[C,S;$R]=O)-;@[C,S;$R](=O)):1]>>[*-:1] PROT_A_31\n\
#\n\
#  CH with three moderate electron withdrawing groups \n\
#[CH]([$EW1,$EW2])([$EW1])[$EW1]\n\
#Prt 1  -1\n\
[H][$([CH]([$EW1,$EW2])([$EW1])[$EW1]):1]>>[*-:1] PROT_A_32\n\
#\n\
#  CH with two strong electron withdrawing groups \n\
#  (e.g. sulfonyl nitromethanes)\n\
#[C;H,H2;!-]([$EW2])[$EW2]\n\
#Prt 1  -1     \n\
[H][$([C;H,H2;!-]([$EW2])[$EW2]):1]>>[*-:1] PROT_A_33\n\
#\n\
#  Barbituric acid and N-alkyl derivatives [pKa: 4-4.5]\n\
# modify this smart to avoid duplicate effect with Cyclic 1,3-diketones smarts editing\n\
#[C;H,H2]1C(=O)[NX3]C(=O)[NX3]C1=O - this was not active in the original file (DAC, 15/8/2013)\n\
#[C;H,H2;!-]1C(=O)[NX3]C(=O)[NX3]C1=O - this one was\n\
#Prt 1  -1\n\
[H][$([C;H,H2;!-]1C(=O)[NX3]C(=O)[NX3]C1=O):1]>>[*-:1] PROT_A_34\n\
#\n\
#-------------------------------------------------------------\n\
#\n\
#  Guanidines & amidines:  Move H away from nitrogen \n\
#  bearing pi-acceptor group\n\
#\n\
#[$nh,$nr,$nph;!$(N[$g2])]=C([$am,C,c,O,S])-[N;X3;H;!+][$g2]\n\
#Hyd  1   1\n\
#Hyd  4  -1\n\
#Bnd  1   2   1\n\
#Bnd  2   4   2\n\
[$nh,$nr,$nph;!$(N[$g2]):1]=[C:2]([$am,C,c,O,S:3])-[N;X3;H;!+:4]([H])[$g2:5]>>[H][*:1]-[*:2]([*:3])=[*:4][*:5] PROT_A_35\n\
#\n\
#[$nh,$nr]=C([$am,C,c,O,S])-[N;X3;H;!+]c\n\
#Hyd  1   1\n\
#Hyd  4  -1\n\
#Bnd  1   2   1\n\
#Bnd  2   4   2\n\
[$nh,$nr:1]=[C:2]([$am,C,c,O,S:3])-[N;X3;H;!+:4]([H])[c:5]>>[H][*:1]-[*:2]([*:3])=[*:4][*:5] PROT_A_36\n\
#\n\
#------------------------------------------------------------";

}

#endif // TAUT_ENUM_PROTONATE_A_SMK
